Bovilis IBR Marker Live

1 x 5 dose

Lyophilisate and solvent for suspension for injection

Active substance

Bovine rhinotracheitis / Bovine herpes virus (BHV1) / (IBR1) (strain GK/D) (attenuated)

ATC code

QI02AD01 Bovine rhinotracheitis virus (IBR)

QI02AD Live viral vaccines

QI02A Immunologicals for cattle

QI02 Immunologicals for bovidae

QI Immunologicals

Species

Cattle.

Indications

Active immunisation of cattle to reduce the intensity and duration of the clinical respiratory signs induced by an infection with BHV-1 and to reduce nasal excretion of field virus.

Onset of immunity:

An increase in immunity was demonstrated 4 days after intranasal vaccination and 14 days after intramuscular vaccination of 3 month old seronegative animals.

Duration of immunity:

After intranasal administration to 2 week old calves immunity lasts at least until the age of 3-4 months. In the presence of maternally derived antibodies, the protection of the vaccine may not be complete until a second vaccination. This second vaccination should be administered at 3-4 months of age and will result in protective immunity that lasts for at least 6 months.

Single intranasal or intramuscular vaccination of 3 months old animals provides protective immunity (reduction of clinical signs and reduction of viral excretion), which was demonstrated via challenge 3 weeks after vaccination. Reduction of viral excretion is maintained for at least 6 months after single vaccination.

Revaccination to ensure protection after the initial 6 month protection period has elapsed will result in protective immunity that lasts for 12 months.

Specific information:

No information is available on the efficacy of the vaccine to prevent a latent wild virus infection or to prevent wild virus re-excretion in the latent carrier.

Dose to be administered and administration route

Reconstitute the lyophilisate with the solvent:

Number of doses per vial	Volume (ml) of solvent needed
5	10
10	20
25	50
50	100
100	200

Dosage: a single dose of 2 ml reconstituted vaccine per animal.

Method of administration:

- from the age of 3 months onwards: intranasal use or intramuscular use.

- at an age between 2 weeks and 3 months: intranasal use.

For intranasal use (1 ml in each nostril), the use of a nozzle is recommended.

Primary vaccination:

- Basic vaccination:

Vaccinate each animal from 3 months of age onwards with one single dose.

- Early protection schedule:

When the first vaccination is given between the age of 2 weeks and 3 months, a second vaccination should be given at an age of 3-4 months.

First revaccination:

The first revaccination should be given 6 months after primary vaccination. Bovilis IBR Marker Inac can alternatively be used for this revaccination.

Subsequent revaccinations:

All following revaccinations should be given at an interval no greater than 12 months. Bovilis IBR Marker Inac can alternatively be used for these revaccinations.

The product literature of Bovilis IBR Marker Inac should be consulted before using it for revaccination.

For revaccination, the lyophilisate may be reconstituted shortly before use with Bovilis BVD for use in cattle from 15 months of age (i.e. those that have previously been vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD). The following instructions should be used:

Bovilis IBR Marker Live Bovilis BVD

5 doses	+ 10 ml
10 doses	+ 20 ml
25 doses	+ 50 ml
50 doses	+ 100 ml

A single dose (2 ml) of Bovilis IBR Marker Live mixed with Bovilis BVD is given intramuscularly.

Shelf life after mixing with Bovilis BVD: 3 hours.

Use sterile vaccination equipment free from disinfectants. To prevent the spread of any infective agents the intranasal equipment should be changed at each animal.

Visual appearance after reconstitution:

- In solvent: colourless to slightly opaque suspension.

- In Bovilis BVD: as specified in the product information for Bovilis BVD alone.

Adverse reactions

Cattle:

Common (1 to 10 animals / 100 animals treated):	Elevated temperature¹ , Nasal discharge² .
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction.

¹ A rise of 1 C may occur up to 5 days post vaccination.

²After intranasal vaccination.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.